Caldera Medical, a leader in women's health medical devices, has acquired Ethicon’s Gynecare TVT™ family of products and will transition the products in the coming months. This strategic milestone builds on Caldera Medical’s 23-year commitment to delivering best-in-class therapies that improve the quality of life for women worldwide.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250320644274/en/
Caldera Medical is expanding its commitment to women’s health with the acquisition of Ethicon’s Gynecare TVT™ family of products! With over two decades of clinical data and trusted efficacy, TVT has been a gold standard in minimally invasive treatment for stress urinary incontinence (SUI). This acquisition ensures a seamless transition for surgeons, patients, and partners, as we maintain the same manufacturing, materials, and dedicated team behind these life-changing products. Our mission is clear: expanding access to proven pelvic health solutions and improving the quality of life for women worldwide.
The TVT product line - consisting of TVT, TVT Exact, TVT-O and TVT Abbrevo, provides minimally invasive treatment options for women with stress urinary incontinence (SUI). As part of the acquisition, Caldera Medical will maintain the same manufacturing facility, materials, and dedicated manufacturing team behind the TVT products, ensuring a seamless transition for surgeons, patients, and partners. With more than two decades of clinical data, including 20-year patient follow-up, the trusted performance and efficacy of TVT remain unchanged.
“This acquisition marks a significant advancement in our mission to transform women’s health,” said Bryon Merade, CEO of Caldera Medical. “By bringing the TVT product line into our portfolio, we reinforce our unwavering commitment to providing safe, effective solutions for surgeons and their patients. We are honored to build on the legacy and expand the reach of this esteemed product family, delivering proven treatments to more women around the world.”
Caldera Medical will expand global customer support for TVT over the next several months and invest in advancing care for a greater number of women. Combining Caldera Medical’s established expertise in pelvic health with TVT’s demonstrated success, the company further solidifies its position as a premier provider of advanced solutions for women. This acquisition follows the September 2023 acquisition of Atlantic Therapeutics with the Innovo non-invasive solution for bladder leaks and the October 2024 acquisition of UVision360 with the Luminelle product line for hysteroscopy and cystoscopy. These acquisitions not only accelerate Caldera Medical’s growth but underscore its dedication to broadening access to life-changing treatments, backed by a legacy of clinical success and a focus on improving patient outcomes.
About Caldera Medical
Caldera Medical is a leading innovator in the field of women’s health, specializing in the development, manufacturing, and marketing of advanced medical devices for the treatment of Stress Urinary Incontinence, Pelvic Organ Prolapse, and gynecologic conditions such as polyps and fibroids. With a focus on minimally invasive surgical solutions, Caldera Medical is committed to its mission of improving the quality of life for women globally. In collaboration with its surgeon partners, Caldera Medical operates the largest humanitarian program in women’s health, with the goal of providing care to one million underserved women worldwide by 2027. Learn more at www.calderamedical.com/.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250320644274/en/
